Genmab (GMAB) Financial Analysis & Valuation | Quarter Chart
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a hum... more
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily i... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $21.30B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | DK | CEO | Jan van de Winkel |
| IPO Date | 2009-06-01 | CAGR | — |
| Employees | 3,119 | Website | www.genmab.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.07% | Total Yield | 0.07% |
GMAB chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $22.92B | P/E | 26.14 | Forward P/E | 21.82 | PEG | -2.93 |
| P/S | 17.04 | P/B | 27.36 | P/CF | 183.04 | P/FCF | 188.03 |
| Sales | $4.13B | Sales 1Y | -68.25% | Sales 3Y | -74.54% | Sales 5Y | -43.57% |
| EPS | $1.33 | EPS 1Y | -85.11% | EPS 3Y | -82.08% | EPS 5Y | -66.61% |
| Sales QoQ | 28.43% | EPS QoQ | 490.36% | Sales QoQ Avg | 6.85% | EPS QoQ Avg | 124.56% |
| Gross Margin | 39.92% | Operating Margin | 13.81% | Profit Margin | 8.17% | ROCE | 11.71% |
| ROA | 6% | ROE | 14% | Altman Z Score | 12.86 | Piotroski Score | 5 |
| Current Ratio | 2.46 | Quick Ratio | 2.44 | Cash Ratio | 1.32 | Op. CF Ratio | 0.04 |
| Debt/Equity | 0.89 | Debt/Assets | 0.42 | Lt Debt/Equity | 0.83 | Lt Debt/Cap. | 0.45 |
| Intrst Cov. | 4.98 | Inventory Turnover | 16.03 | Asset Turnover | 0.77 | Receivables Turnover | 7.53 |
| Enterprise Value | $22.92B | P/E Ratio | 26.14 |
| Forward P/E | 21.82 | PEG Ratio | -2.93 |
| P/S Ratio | 17.04 | P/B Ratio | 27.36 |
| P/CF Ratio | 183.04 | P/FCF Ratio | 188.03 |
| EPS | $1.33 | EPS Growth 1Y | -85.11% |
| EPS Growth 3Y | -82.08% | EPS Growth 5Y | -66.61% |
| Revenue Growth 1Y | -68.25% | Gross Margin | 39.92% |
| Operating Margin | 13.81% | Profit Margin | 8.17% |
| ROE | 14% | ROA | 6% |
| ROCE | 11.71% | Current Ratio | 2.46 |
| Quick Ratio | 2.44 | Cash Ratio | 1.32 |
| Debt/Equity | 0.89 | Interest Coverage | 4.98 |
| Altman Z Score | 12.86 | Piotroski Score | 5 |
Genmab (GMAB) valuation & financials
Genmab (GMAB) has a market capitalization of $21.30B and trades at a price-to-earnings ratio of 26.1. It operates in the Healthcare sector (Biotechnology).
Genmab's revenue grew -68.2% over the last year.
Genmab's next earnings report is scheduled for November 5, 2026 (provider scheduled date); analysts estimate EPS of $0.37. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)